Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 4 | 2017 | 133 | 0.730 |
Why?
|
| Liver Neoplasms | 4 | 2017 | 167 | 0.710 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 433 | 0.650 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 108 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 105 | 0.310 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 360 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 4 | 2022 | 336 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 166 | 0.230 |
Why?
|
| Pyrazines | 2 | 2021 | 26 | 0.210 |
Why?
|
| Pyrazoles | 2 | 2021 | 80 | 0.200 |
Why?
|
| Exanthema | 1 | 2022 | 14 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 21 | 0.180 |
Why?
|
| Quinolones | 1 | 2021 | 22 | 0.170 |
Why?
|
| Immunoconjugates | 1 | 2021 | 21 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 36 | 0.160 |
Why?
|
| Pyridines | 1 | 2021 | 108 | 0.160 |
Why?
|
| Phenylurea Compounds | 2 | 2017 | 17 | 0.140 |
Why?
|
| Niacinamide | 2 | 2017 | 32 | 0.140 |
Why?
|
| SEER Program | 2 | 2016 | 47 | 0.140 |
Why?
|
| Aged | 6 | 2021 | 5627 | 0.140 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2016 | 2 | 0.120 |
Why?
|
| Oligoribonucleotides | 1 | 2016 | 6 | 0.120 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 22 | 0.120 |
Why?
|
| Camptothecin | 1 | 2016 | 16 | 0.120 |
Why?
|
| Humans | 11 | 2022 | 29078 | 0.120 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 6 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2014 | 32 | 0.110 |
Why?
|
| Middle Aged | 5 | 2021 | 7458 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 142 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2016 | 153 | 0.110 |
Why?
|
| Adult | 5 | 2021 | 8080 | 0.100 |
Why?
|
| Comorbidity | 1 | 2014 | 261 | 0.100 |
Why?
|
| Incidence | 1 | 2014 | 574 | 0.100 |
Why?
|
| Female | 7 | 2021 | 15740 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 686 | 0.090 |
Why?
|
| Neoplasms | 1 | 2021 | 882 | 0.090 |
Why?
|
| Male | 6 | 2021 | 14049 | 0.090 |
Why?
|
| Liver | 1 | 2014 | 493 | 0.080 |
Why?
|
| Infant | 1 | 2014 | 1056 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2014 | 1201 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 2855 | 0.080 |
Why?
|
| Adolescent | 2 | 2017 | 3233 | 0.080 |
Why?
|
| Bevacizumab | 1 | 2011 | 106 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 556 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 1360 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 137 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2017 | 2430 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2011 | 631 | 0.070 |
Why?
|
| United States | 1 | 2014 | 2252 | 0.070 |
Why?
|
| Child | 1 | 2014 | 2335 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 303 | 0.060 |
Why?
|
| Nausea | 1 | 2022 | 17 | 0.050 |
Why?
|
| Tears | 1 | 2021 | 10 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 26 | 0.040 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2021 | 9 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 32 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 102 | 0.040 |
Why?
|
| Cornea | 1 | 2021 | 72 | 0.040 |
Why?
|
| Epistaxis | 1 | 2017 | 7 | 0.030 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 28 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 35 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 11 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2016 | 13 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 236 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 278 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2016 | 27 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 54 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2016 | 14 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2016 | 20 | 0.030 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 17 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2016 | 42 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 433 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 237 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 480 | 0.030 |
Why?
|
| Animals | 2 | 2021 | 10756 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 165 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 465 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 473 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 815 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 179 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 668 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 740 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 301 | 0.030 |
Why?
|
| Smoking | 1 | 2016 | 480 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 4845 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 2138 | 0.020 |
Why?
|